ApoA-I-Directed Therapies for the Management of Atherosclerosis

Area of Science:

• Cardiovascular Research
• Pharmacology
• Biochemistry

Background:

• Recent reports challenge the established atheroprotective role of high-density lipoprotein cholesterol (HDL-C).
• Despite these doubts, significant research supports targeting HDL function for therapeutic benefit.
• Focus is shifting from increasing HDL-C levels to enhancing HDL's functional capacity.

Purpose of the Study:

• To review pharmacological strategies aimed at improving HDL function.
• To explore interventions targeting apolipoprotein A-I (apoA-I) for atherosclerotic risk reduction.
• To discuss novel therapeutic approaches for cardiovascular disease.

Main Methods:

• Review of scientific literature on HDL-C and cardiovascular risk.
• Analysis of pharmacological interventions targeting HDL function.
• Categorization of interventions into small molecule pharmaceuticals, mimetic peptides, and apoA-I infusions.

Main Results:

• Development of diverse pharmacological agents that modulate HDL function.
• Identification of small molecule drugs, HDL mimetic peptides, and apoA-I infusions as key strategies.
• Evidence supporting the potential of these interventions in managing atherosclerosis.

Conclusions:

• Pharmacological enhancement of HDL function, rather than simply increasing HDL-C levels, shows promise.
• Targeting apoA-I and HDL function represents a viable therapeutic avenue for reducing atherosclerotic risk.
• Future research should focus on the clinical efficacy of these novel HDL-targeting agents.